Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Pharmacokinet ; 56(10): 1103-1113, 2017 10.
Article in English | MEDLINE | ID: mdl-28229375

ABSTRACT

Ombitasvir is a potent, nonstructural protein 5A inhibitor of the hepatitis C virus (HCV) that is used in combination with other direct-acting antivirals for the treatment of chronic HCV infection. Ombitasvir is predominantly metabolized by amide hydrolysis followed by oxidative metabolism and is a substrate of P-glycoprotein. Ombitasvir displays linear pharmacokinetics with minimal accumulation and is eliminated via metabolism and biliary excretion. A negligible amount of unchanged drug is excreted in urine. Exposures are comparable across Chinese, Japanese, and non-Asian subjects. The pharmacokinetic characteristics of ombitasvir are similar in healthy subjects and HCV-infected patients, and are not appreciably altered by hepatic or renal impairment. Results from several drug interaction studies demonstrated that ombitasvir has a low potential for drug interactions.


Subject(s)
Anilides/pharmacokinetics , Antiviral Agents/pharmacokinetics , Carbamates/pharmacokinetics , Hepacivirus/drug effects , Hepatitis C, Chronic/blood , Hepatitis C, Chronic/drug therapy , Anilides/administration & dosage , Anilides/chemistry , Animals , Antiviral Agents/administration & dosage , Antiviral Agents/chemistry , Carbamates/administration & dosage , Carbamates/chemistry , Drug Interactions/physiology , Drug Therapy, Combination , Food-Drug Interactions/physiology , Humans , Proline , Valine
2.
Eur J Drug Metab Pharmacokinet ; 42(2): 333-339, 2017 Apr.
Article in English | MEDLINE | ID: mdl-27165046

ABSTRACT

BACKGROUND AND AIMS: Ombitasvir, paritaprevir (given with low-dose ritonavir), and dasabuvir are direct-acting antivirals (DAAs) used with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) infection. The objective of this analysis was to evaluate the effect of renal function as determined by creatinine clearance (CrCL) on the pharmacokinetics of the DAAs, ritonavir, and ribavirin in HCV genotype 1-infected patients with or without cirrhosis. METHODS: Total exposure, measured by area under the plasma concentration-time curve (AUC), was generated for the DAAs, ritonavir, and ribavirin using population pharmacokinetic modeling of data (N = 2093 patients) from 6 Phase 3 studies and 1 Phase 2 study. The effect of CrCL on the AUC values of each DAA, ritonavir, and ribavirin was separately evaluated and adjusted for any significant patient-specific covariates including, age, sex, body weight, cirrhosis, and Asian race in multiple linear regression analysis. Using the final models, AUC values were predicted for patients with normal renal function (CrCL = 105 mL/min), mild renal impairment (CrCL = 75 mL/min) and moderate renal impairment (CrCL = 45 mL/min). RESULTS: CrCL was not a statistically significant predictor of DAA or ritonavir AUC values. Age, sex, and cirrhosis were significant covariates for the AUC values of all the DAAs and body weight was a significant covariate for the AUC values of ombitasvir and dasabuvir. Asian race was significant only for dasabuvir. Only age and sex were statistically significant predictors for the AUC values of ritonavir. CrCL showed a significant relationship with the ribavirin AUC values, consistent with ribavirin's renal excretion. Age, sex, body weight, and cirrhosis were also significant covariates for the AUC values of ribavirin. The DAA and ritonavir AUC values were comparable (≤10 % difference) among different levels of renal function, while ribavirin AUC values were up to 17 % higher in mild/moderate renal impairment compared with normal renal function. CONCLUSIONS: No dose adjustments are needed for the 3D regimen in HCV genotype-1 infected patients with mild or moderate renal impairment. Ribavirin doses should be adjusted for renal impairment as recommended in the ribavirin label.


Subject(s)
Antiviral Agents/pharmacokinetics , Hepatitis C, Chronic/complications , Renal Insufficiency/complications , 2-Naphthylamine , Adolescent , Adult , Aged , Anilides/administration & dosage , Anilides/pharmacokinetics , Antiviral Agents/administration & dosage , Area Under Curve , Carbamates/administration & dosage , Carbamates/pharmacokinetics , Clinical Trials, Phase II as Topic , Clinical Trials, Phase III as Topic , Cyclopropanes , Dose-Response Relationship, Drug , Drug Therapy, Combination , Female , Genotype , Hepacivirus/genetics , Hepacivirus/isolation & purification , Hepatitis C, Chronic/virology , Humans , Kidney Function Tests , Lactams, Macrocyclic , Macrocyclic Compounds/administration & dosage , Macrocyclic Compounds/pharmacokinetics , Male , Middle Aged , Models, Biological , Proline/analogs & derivatives , Ribavirin/administration & dosage , Ribavirin/pharmacokinetics , Ritonavir/administration & dosage , Ritonavir/pharmacokinetics , Sulfonamides/administration & dosage , Sulfonamides/pharmacokinetics , Uracil/administration & dosage , Uracil/analogs & derivatives , Uracil/pharmacokinetics , Valine , Young Adult
3.
Antivir Ther ; 21(8): 707-714, 2016.
Article in English | MEDLINE | ID: mdl-27584548

ABSTRACT

BACKGROUND: The three drug direct-acting antiviral regimen (3D regimen) of ombitasvir, paritaprevir/ritonavir and dasabuvir, with and without ribavirin, was evaluated in one Phase II trial and six Phase III trials in over 2,300 HCV genotype-1-infected patients. Patients continued taking their protocol-permitted co-medications while receiving the 3D ± ribavirin regimen. The effects of the co-medications on exposures of the 3D regimen and ribavirin were examined. METHODS: Population pharmacokinetic model-predicted steady-state area under the curve (AUC24,ss) values were evaluated in the presence/absence of the co-medications. Interactions resulting in a greater than 50% reduction or 100% increase in an AUC24,ss value were examined as covariates for an effect on apparent clearance (CL/F). RESULTS: More than 1,200 co-medications belonging to 15 drug classes and/or 19 enzyme and transporter inhibitor and/or inducer categories were used concomitantly with the 3D regimen in the trials. Approximately 1,500 patients (65%) in Phase III trials received two or more co-medications from multiple drug classes or categories. No co-medication class/category decreased or increased ombitasvir, dasabuvir, ritonavir or ribavirin AUC24,ss by more than half or twofold, respectively. Opioids, antipsychotics, anti-epileptics, antidiabetics and non-ethinyl estradiol-containing hormone replacement therapies appeared to have an effect (AUC24,ss ratio ≤0.5 or ≥2.0) on paritaprevir exposures. However, when these classes were included in the paritaprevir population pharmacokinetic model, only opioids and antidiabetics had a statistically significant effect on CL/F, but with no clinically meaningful increase in exposures (≤55%). CONCLUSIONS: No dose adjustment is necessary for the 3D ± ribavirin regimen when used with the co-medications included in this analysis as there were no clinically meaningful effects on exposures of the DAAs.


Subject(s)
Antiviral Agents/pharmacokinetics , HIV Infections/drug therapy , 2-Naphthylamine , Anilides/administration & dosage , Anilides/pharmacokinetics , Antiviral Agents/administration & dosage , Antiviral Agents/adverse effects , Area Under Curve , Carbamates/administration & dosage , Carbamates/pharmacokinetics , Clinical Trials, Phase II as Topic , Clinical Trials, Phase III as Topic , Cyclopropanes , Drug Interactions , Drug Therapy, Combination , Humans , Lactams, Macrocyclic , Macrocyclic Compounds/administration & dosage , Macrocyclic Compounds/pharmacokinetics , Proline/analogs & derivatives , Ribavirin/administration & dosage , Ribavirin/pharmacokinetics , Ritonavir/administration & dosage , Ritonavir/pharmacokinetics , Sulfonamides/administration & dosage , Sulfonamides/pharmacokinetics , Uracil/administration & dosage , Uracil/analogs & derivatives , Uracil/pharmacokinetics , Valine
4.
Ther Drug Monit ; 38(5): 640-5, 2016 10.
Article in English | MEDLINE | ID: mdl-27310199

ABSTRACT

BACKGROUND: Interactions between tacrolimus and cyclosporine (CSA) and the 3 direct-acting antiviral regimen (3D) of ombitasvir, paritaprevir/ritonavir, and dasabuvir necessitate a priori dose adjustments for the immunosuppressants to achieve desired levels. Modeling and simulations based on data in healthy subjects predicted that tacrolimus 0.5 mg every 7 days or 0.2 mg every 3 days, and CSA at one-fifth the total daily dose administered once daily, would achieve desired trough concentrations (Ctrough) during 3D treatment. The success of these dosing recommendations was evaluated by analyzing pharmacokinetic data from liver transplant recipients in the CORAL-I study. METHODS: A population pharmacokinetic model was developed using tacrolimus dosing and Ctrough data before and during 3D treatment (n = 29). The model was used to simulate various tacrolimus dosing regimens and predict tacrolimus concentration-time profiles during 3D treatment. CSA Ctrough data before and during 3D treatment (n = 5) were also summarized. RESULTS: A one-compartment model with first-order absorption adequately described tacrolimus pharmacokinetic profiles during the first 4 weeks of 3D treatment. Estimated tacrolimus Ctrough values (median; interquartile range) before and during 3D treatment were comparable (5.7 ng/mL; 4.9-6.5 ng/mL versus 5.2 ng/mL; 4.2-6.3 ng/mL, respectively). Based on simulations, in a patient with a starting Ctrough of 6 ng/mL, 0.5 mg tacrolimus every 7 or 14 days or 0.2 mg tacrolimus every 3 days will result in Ctrough levels of 6-9 ng/mL, 4-6 ng/mL, and 6-10 ng/mL, respectively, during 3D treatment. For CSA, Ctrough values (median; interquartile range) before and during 3D treatment were comparable (126 ng/mL; 94-140 ng/mL versus 104 ng/mL; 82-140 ng/mL). CONCLUSIONS: Observed data for tacrolimus and CSA in liver transplant recipients confirm that the recommended dosing strategies are valid and therapeutic levels of immunosuppression can be maintained during 3D treatment.


Subject(s)
Anilides/pharmacology , Carbamates/pharmacology , Cyclosporine/pharmacokinetics , Macrocyclic Compounds/pharmacology , Sulfonamides/pharmacology , Tacrolimus/pharmacokinetics , Uracil/analogs & derivatives , 2-Naphthylamine , Adolescent , Adult , Aged , Antiviral Agents/pharmacology , Cyclopropanes , Drug Dosage Calculations , Drug Therapy, Combination , Female , Hepatitis C/drug therapy , Humans , Immunosuppressive Agents/pharmacokinetics , Lactams, Macrocyclic , Liver Transplantation , Male , Middle Aged , Models, Biological , Proline/analogs & derivatives , Ritonavir/pharmacology , Uracil/pharmacology , Valine , Young Adult
5.
Clin Pharmacokinet ; 55(3): 275-95, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26330025

ABSTRACT

The development of direct-acting antiviral (DAA) agents has reinvigorated the treatment of hepatitis C virus infection. The availability of multiple DAA agents and drug combinations has enabled the transition to interferon-free therapy that is applicable to a broad range of patients. However, these DAA combinations are not without drug-drug interactions (DDIs). As every possible DDI permutation cannot be evaluated in a clinical study, guidance is needed for healthcare providers to avoid or minimize drug interaction risk. In this review, we evaluated the DDI potential of the novel three-DAA combination of ombitasvir, paritaprevir, ritonavir, and dasabuvir (the 3D regimen) with more than 200 drugs representing 19 therapeutic drug classes. Outcomes of these DDI studies were compared with the metabolism and elimination routes of prospective concomitant medications to develop mechanism-based and drug-specific guidance on interaction potential. This analysis revealed that the 3D regimen is compatible with many of the drugs that are commonly prescribed to patients with hepatitis C virus infection. Where interaction is possible, risk can be mitigated by paying careful attention to concomitant medications, adjusting drug dosage as needed, and monitoring patient response and/or clinical parameters.


Subject(s)
Anilides/administration & dosage , Antiviral Agents/administration & dosage , Carbamates/administration & dosage , Hepatitis C/drug therapy , Macrocyclic Compounds/administration & dosage , Ritonavir/administration & dosage , Anilides/adverse effects , Anilides/pharmacokinetics , Anilides/therapeutic use , Antiviral Agents/adverse effects , Antiviral Agents/pharmacokinetics , Antiviral Agents/therapeutic use , Carbamates/adverse effects , Carbamates/pharmacokinetics , Carbamates/therapeutic use , Cyclopropanes , Drug Combinations , Drug Interactions , Humans , Lactams, Macrocyclic , Macrocyclic Compounds/adverse effects , Macrocyclic Compounds/pharmacokinetics , Macrocyclic Compounds/therapeutic use , Proline/analogs & derivatives , Ritonavir/adverse effects , Ritonavir/pharmacokinetics , Ritonavir/therapeutic use , Sulfonamides , Valine
6.
Antimicrob Agents Chemother ; 60(1): 105-14, 2016 01.
Article in English | MEDLINE | ID: mdl-26459906

ABSTRACT

The two direct-acting antiviral (2D) regimen of ombitasvir and paritaprevir (administered with low-dose ritonavir) is being developed for treatment of genotype subtype 1b and genotypes 2 and 4 chronic hepatitis C virus (HCV) infection. Drug-drug interactions were evaluated in healthy volunteers to develop dosing recommendations for HCV-infected subjects. Mechanism-based interactions were evaluated for ketoconazole, pravastatin, rosuvastatin, digoxin, warfarin, and omeprazole. Interactions were also evaluated for duloxetine, escitalopram, methadone, and buprenorphine-naloxone. Ratios of geometric means with 90% confidence intervals for the maximum plasma concentration and the area under the plasma concentration-time curve were estimated to assess the magnitude of the interactions. For most medications, coadministration with the 2D regimen resulted in a <50% change in exposures. Ketoconazole, digoxin, pravastatin, and rosuvastatin exposures increased by up to 105%, 58%, 76%, and 161%, respectively, and omeprazole exposures decreased by approximately 50%. Clinically meaningful changes in ombitasvir, paritaprevir, or ritonavir exposures were not observed. In summary, all 11 medications evaluated can be coadministered with the 2D regimen, with most medications requiring no dose adjustment. Ketoconazole, digoxin, pravastatin, and rosuvastatin require lower doses, and omeprazole may require a higher dose. No dose adjustment is required for the 2D regimen.


Subject(s)
Anilides/pharmacokinetics , Antiviral Agents/pharmacokinetics , Carbamates/pharmacokinetics , Macrocyclic Compounds/pharmacokinetics , Ritonavir/pharmacokinetics , Adult , Anilides/blood , Antacids/blood , Antacids/pharmacokinetics , Anti-Arrhythmia Agents/blood , Anti-Arrhythmia Agents/pharmacokinetics , Anticoagulants/blood , Anticoagulants/pharmacokinetics , Antidepressive Agents/blood , Antidepressive Agents/pharmacokinetics , Antifungal Agents/blood , Antifungal Agents/pharmacokinetics , Antiviral Agents/blood , Area Under Curve , Carbamates/blood , Cyclopropanes , Drug Interactions , Drug Therapy, Combination , Female , Healthy Volunteers , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/blood , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacokinetics , Lactams, Macrocyclic , Macrocyclic Compounds/blood , Male , Middle Aged , Multivariate Analysis , Narcotic Antagonists/blood , Narcotic Antagonists/pharmacokinetics , Proline/analogs & derivatives , Ritonavir/blood , Sulfonamides , Valine
7.
Clin Ther ; 37(11): 2560-71, 2015 11 01.
Article in English | MEDLINE | ID: mdl-26505529

ABSTRACT

PURPOSE: The 2 direct-acting antiviral combination (2D) of ombitasvir and paritaprevir (coadministered with ritonavir) is being evaluated for the treatment of chronic hepatitis C virus infection in Japan. Ursodeoxycholic acid (UDCA) and glycyrrhizin (GCR) are hepatoprotective agents widely used in Japan. A drug-drug interaction (DDI) study was conducted to guide dosing recommendations for UDCA and GCR when coadministered with the 2D regimen. METHODS: DDIs between the 2D regimen (ombitasvir/paritaprevir/ritonavir 25/150/100 mg orally once daily) and UDCA (50 mg orally 3 times daily) or GCR (80 mg intravenously once daily) were evaluated in a 2-arm, multiple-dose study in 24 Japanese healthy subjects under fed conditions. Pharmacokinetic and safety evaluations were performed when UDCA or GCR and the 2D regimen were administered alone and during coadministration. Exposures from coadministration of the 2D regimen plus UDCA or GCR versus the 2D regimen, UDCA, or GCR alone were compared using repeated-measures analyses of natural logarithms of the maximum plasma concentration (Cmax) and area under the curve (AUC). FINDINGS: After coadministration of the 2D regimen and UDCA, steady-state exposures (Cmax and AUC) of ombitasvir, paritaprevir, and ritonavir showed a ≤9% change, and UDCA exposures showed a ≤20% change compared with administration alone. When the 2D regimen and GCR were coadministered, steady-state exposures of ombitasvir, paritaprevir, and ritonavir were not affected (≤9% change), GCR AUC increased by 49%, and GCR Cmax was unaffected (<1% change). IMPLICATIONS: No dose adjustment is needed for UDCA, GCR, or the 2D regimen when UDCA or GCR is coadministered with the 2D regimen in hepatitis C virus-infected patients under fed conditions. Clinical monitoring of patients using GCR is recommended due to an approximately 50% increase in GCR AUC when coadministered with the 2D regimen.


Subject(s)
Anilides/administration & dosage , Carbamates/administration & dosage , Glycyrrhizic Acid/administration & dosage , Macrocyclic Compounds/administration & dosage , Ritonavir/administration & dosage , Ursodeoxycholic Acid/administration & dosage , Adult , Antiviral Agents/administration & dosage , Antiviral Agents/therapeutic use , Cyclopropanes , Drug Interactions , Drug Therapy, Combination , Hepatitis C, Chronic/drug therapy , Humans , Japan , Lactams, Macrocyclic , Male , Proline/analogs & derivatives , Sulfonamides , Valine , Young Adult
8.
J Hepatol ; 63(1): 20-9, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25646891

ABSTRACT

BACKGROUND & AIMS: Paritaprevir (administered with ritonavir, PTV/r), ombitasvir (OBV), and dasabuvir (DSV) are direct-acting antiviral agents (DAAs) for the treatment of chronic hepatitis C virus (HCV) infection. Thirteen studies were conducted to characterize drug-drug interactions for the 3D regimen of OBV, PTV/r, and DSV and various medications in healthy volunteers to inform dosing recommendations in HCV-infected patients. METHODS: Mechanism-based drug-drug interactions were evaluated for gemfibrozil, ketoconazole, carbamazepine, warfarin, omeprazole, digoxin, pravastatin, and rosuvastatin. Drug-drug interactions with medications commonly used in HCV-infected patients were evaluated for amlodipine, furosemide, alprazolam, zolpidem, duloxetine, escitalopram, methadone, buprenorphine/naloxone, and oral contraceptives. Ratios of geometric means with 90% confidence intervals for maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) were used to determine the magnitude of interaction. RESULTS: Coadministration with the 3D regimen of OBV, PTV/r, and DSV resulted in a <2-fold change in mean Cmax and AUC for most medications and the DAAs, indicating minimal to modest interactions. Carbamazepine decreased PTV, ritonavir, and DSV exposures substantially, while gemfibrozil increased DSV exposures substantially. Although coadministration with ethinyl estradiol-containing contraceptives resulted in elevated alanine aminotransferase levels, coadministration with a progestin-only contraceptive did not. CONCLUSIONS: The majority of medications can be coadministered with the 3D regimen of OBV, PTV/r, and DSV without dose adjustment, or with clinical monitoring or dose adjustment. Although no dose adjustment is necessary for the 3D regimen when coadministered with 17 of the 20 medications, coadministration with gemfibrozil, carbamazepine, or ethinyl estradiol-containing contraceptives is contraindicated.


Subject(s)
Anilides/administration & dosage , Carbamates/administration & dosage , Hepatitis C, Chronic/drug therapy , Macrocyclic Compounds/administration & dosage , Ritonavir/administration & dosage , Sulfonamides/administration & dosage , Uracil/analogs & derivatives , 2-Naphthylamine , Administration, Oral , Adolescent , Adult , Anilides/pharmacokinetics , Antiviral Agents/administration & dosage , Antiviral Agents/pharmacokinetics , Carbamates/pharmacokinetics , Cyclopropanes , Drug Interactions , Drug Therapy, Combination , Female , Hepacivirus/immunology , Hepatitis C Antibodies/immunology , Hepatitis C, Chronic/blood , Hepatitis C, Chronic/virology , Humans , Lactams, Macrocyclic , Macrocyclic Compounds/pharmacokinetics , Male , Middle Aged , Proline/analogs & derivatives , Ritonavir/pharmacokinetics , Sulfonamides/pharmacokinetics , Uracil/administration & dosage , Uracil/pharmacokinetics , Valine , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...